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Abstract
Background: Recently accumulated evidence suggests that Raf kinase inhibitor protein (RKIP) participates in
regulation of many signaling pathways and plays an important role in tumorigenesis and tumor metastasis.
However, studies investigating the role of RKIP in colorectal cancer have not been reported. The aim of this study
was to investigate the role of RKIP on colorectal cancer cell differentiation, progression and its correlation with
chemosensitivity.
Results: Immunohistochemical analysis revealed that RKIP expression was higher in non-neoplastic colorectal tissue
(NCRCT) and colorectal cancer tissue (CRCT) than that in metastatic lymph node tissue (MLNT) (P <0.05). P-ERK
protein expression was higher in MLNT and CRCT than that in NCRCT (P = 0.02). Immunocytochemical analysis further
revealed that RKIP expression was higher in the well differentiated cell line SW1116 as compared to that in the poorly
differentiated cell line LoVo. Matrigel invasive assay demonstrated that the inhibition of RKIP by short hairpin RNA
(shRNA) 271 transfection significantly increased the number of migrated cells (90.67 ± 4.04 vs. 37.33 ± 2.51, P <0.05),
whereas over-expression of RKIP by PEBP-1 plasmid transfection significantly suppressed the number of migrated cells
(79.24 ± 5.18 vs. 154.33 ± 7.25, P <0.05). Meanwhile, down-regulation of RKIP induced an increase in the cell survival rate
by inhibiting apoptosis induced by hydroxycamptothecine.
Conclusions: RKIP was also found to be associated with cell differentiation, with a higher activity in well differentiated
colorectal cancer cells than in poorly differentiated ones. The upregulated expression of RKIP in colorectal cancer cells
inhibited cell invasion and metastasis, while downregulation of RKIP reduced chemosensitivity by inhibiting apoptosis
induced by HCPT.
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Background
The Raf kinase inhibitor protein (RKIP), a member of
an evolutionarily conserved family of
phosphatidylethanolamine-binding proteins (PEBPs),
has been recognized as a representative of a new class of
modulators of signaling cascades that serve to maintain the
balance of biological systems. RKIP inhibits kinase signal-
ing pathways and metastasis. A vast array of studies have
been conducted to understand the role of RKIP in various
malignancies such as melanoma [1], prostate cancer [2],
breast cancer [3], gastric cancer [4], glioblastoma [5], lung
cancer [6], and myelogenous leukemia [7]. Most notably,
RKIP has been identified as a modulator of extracellular
signal-regulated kinase (ERK) [8], nuclear factor-kappa B
(NFkB) [9], and G protein coupled receptor (GPCR) [10,
11] signaling cascades. Moreover, RKIP has been impli-
cated in tumor biology. Down-regulation of RKIP signifi-
cantly correlated with radio-resistance-induced relapse
[12]. RKIP sensitizes prostate and breast cancer cells to
drug-induced apoptosis [13]. RKIP as a suppressor of me-
tastasis has been confirmed as a predictor of cancer pro-
gression and is even being considered as a potential
therapeutic target.
Recently, RKIP was found to inhibit proliferation of
activated hepatic stellate cells by down-regulation of
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mitogen-activated protein kinase (MAPK) signaling, but
was found to promote the migration of hepatic stellate
cells and wound closure [14]. Surprisingly, in the merkel
cell carcinoma cell line UISO, RKIP knockdown does
not alter proliferation or chemosensitivity to cisplatin,
and has no effect on blocking the MAP kinase pathway
[15]. RKIP does not appear to play exactly the same role in
different cancers and non-malignant cells. This may be be-
cause of the diverse molecular functioning milieu, different
cell proliferation signaling pathways active in different tis-
sues and other mechanisms that are as yet unknown.
In developed countries, colorectal cancer (CRC) is the
third-most frequent cancer and the second-most common
cause of cancer-related death [16]. Chemotherapeutic drug
resistance remains a major obstacle to the successful treat-
ment of colorectal cancer. RKIP silencing has been corre-
lated significantly with KEAP1 degradation and bestowed
resistance to cisplatin by up-regulating NRF2 gene in
HER-293 cells. Also, expression levels of RKIP/KEAP1
have relationship with the extent of apoptosis after
treatment with adriamycin in HT29 cells [17]. In nor-
mal colonic mucosa, cytoplasmic RKIP expression was
found in 100 % of cells [18]. A study suggested that
RKIP is probably a downstream effector in TWEAK
(Tumor necrosis factor-like weak inducer of apoptosis)
mediated invasion inhibition. Knockdown of RKIP ex-
pression in HCT116 cells by short hairpin RNA
(shRNA) resulted in increased invasiveness [19]. Loss
of RKIP was also found to be associated with N stage
disease, the presence of vascular invasion, metastasis
and worse survival time in mismatch repair–proficient
CRC [18]. RKIP expression in primary CRCs can be
useful for identifying early-stage CRC patients at risk of
relapse [20]. It is plausible that RKIP plays an import-
ant role in the occurrence and development of colorec-
tal cancer. However, few studies exploring the role of
RKIP in colorectal cancer have been reported and the
specific mechanism still remains unresolved.
In our paper, we shall first investigate the effect of RKIP
on differentiation, invasion and metastasis of colorectal
cancer cells, both in vivo and in vitro. Later, the associ-
ation between RKIP and chemosensitivity to hydroxy-




Two human colorectal cancer cell lines SW1116 and
SW480 were cultured in RPMI 1640 medium (Gibco,
Carlsbad, CA) with 10 % fetal bovine serum. LoVo
cells (human colon adenocarcinoma cell line) were cul-
tured in F-12 k medium with 10 % fetal bovine serum.
Two other human colorectal cancer lines, HT-29 and
HCT-116 were cultured in McCoy’s 5A medium
(Sigma, Louis, MO) with 10 % fetal bovine serum.
Caco-2 (human colon adenocarcinoma cell line) cells
were cultured in DMEM medium (Gibco, Carlsbad,
CA) with 10 % fetal bovine serum. All cells were incu-
bated at 37 °C in humidified 5 % CO2. HCPT-resistant
cell line of human colon cancer cell, SW1116/HCPT,
was developed by stepwise increasing concentration
method [21].
Patients and tissue samples
Thirty non-neoplastic colorectal tissue (NCRCT) sam-
ples and 30 colorectal cancer tissue (CRCT) samples
were surgically obtained from patients admitted from
2007 to 2009 in the Department of General Surgery at
Shanghai Renji Hospital, China. Another 30 matching
metastatic lymph node tissue (MLNT) samples archived
in formalin-fixed paraffin-embedded tissue blocks were
obtained from Department of Pathology, Shanghai Renji
Hospital, China.
Immunohistochemistry and immunocytochemistry
For immunohistochemistry (IHC), sections of paraffin-
embedded tissues were deparaffinized in xylene, rehy-
drated in graded alcohol solutions, and treated with an
antigen retrieval solution (10 mmol/L sodium citrate
buffer, pH 6.0). For IHC, cells were incubated at the
density of 2 × 104 cells/cm2 in 6-well culture plate with
glass slice. A three-step streptavidin-biotin horseradish
peroxidase method was used, and the expression of RKIP
and pERK was examined with the primary antibodies
(RKIP, Santa Cruz, dilution 1:200; pERK, Santa Cruz, dilu-
tion 1:50) using the SP kit (ZYMED, San Diego, America),
according to the manufacturer’s instructions. Protein ex-
pression was quantified based on a 3-point positive scale
(+: 0 to 2; ++: 3 to 4; +++: 5 to 9). The scale ranking
equaled the product of staining intensity score (4-point
scale: negative-0; weak-1; intermediate-2; and strong-3)
and staining extent score (percentage of positive tumor
cells: 0–0 % to 10 %; 1–15 % to 50 %; 2–51 % to 75 % and
3–>75 %). The percentage of positive cells was calculated
by counting more than 100 cancer cells in randomly se-
lected high-power fields (400×). All samples were analyzed
by two senior pathologists.
Real-time polymerase chain reaction
One μg of RNA was reverse transcribed using RT kit
(Takara, Tokyo, Japan). Quantitative real-time polymerase
chain reaction (PCR) was performed with a SYBR Green
real-time premix kit (Takara, Tokyo, Japan). Forward (F)
and reverse (R) primer sequences were as follows:
RKIP(F)5′-agcagtggcacagtcctc-3′,(R)5′-tggtctccagatcggttg-
3′; GAPDH(F)5′-gcaccgtcaaggctgagaac-3′, (R) 5′-atggtggtg
aagacgccagt-3′. PCR was performed for 30s at 95 °C, 5 s at
95 °C and 31 s at 60 °C for 40 cycles.
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Stable transfection and G418 screening of stable
expression cell lines
PGPU6/GFP/Neo-PEBP1-501/271/376 (RKIP shRNA vec-
tor, RKIP GenBank Number: NM-002576) and PGPU6/
GFP/Neo-sh NC (negative control) were obtained from
Gene Pharma, Inc. (Shanghai, Co). SW1116 cells were
transfected with each shRNA using Lipofectamine 2000
reagent (Invitrogen, Carlsbad, CA) as per the manufac-
turer’s protocol. The silencing effect of RKIP was con-
firmed by real-time PCR and Western blot analysis.
SW1116 cells were transfected with the shRNA that had
the best silencing effect, and screened by G418 (Sigma).
The best screening concentration of G418 for SW1116
cells was 800 μg/mL. After one month of selection in
RIPM-1640 medium containing 800 mg/mL G418. In-
dividual neomycin-resistant colonies were isolated and
expanded.
Western blotting
Western blot analysis was performed using the standard
methodology as described previously [22]. The cells were
lysed in RIPA Lysis Buffer (Beyotime, Shang-hai, CH);
equal amount of protein (100 μg/lane) from whole-cell
lysates were subjected to SDS-PAGE. Proteins were
transferred to microporous PVDF membranes (Millipore,
Massachusetts, CA) and were probed with specific pri-
mary antibodies, followed by the appropriate HRP-
conjugated secondary antibodies (Pierce, Rockford,
USA). The antibodies used in this study were rabbit
monoclonal antibody RKIP (Santa Cruz, Inc, 1:200
dilution), rabbit polyclonal antibody P-ERK (Santa Cruz,
Inc, 1:100 dilution), GAPDH (Kang-chen, Shang-hai, CH.
1:1000). Proteins were detected using the enhanced
chemiluminescence detection kit (Super Signal West
Femto Substrate, Pierce).
Apoptosis assay
Apoptosis was demonstrated using Annexin V-FITC
apoptosis detection kit (Abcam, USA) according to man-
ufacturer’s protocol. About 1 × 106 cells were collected
and immediately analysed using a flow cytometer (BD,
San Diego, CA).
Matrigel invasion assay
Matrigel invasion assay was performed using transwell
insert chamber (8.0 μm pore polycarbonate membranes,
Corning, Inc.) coated with Matrigel (BD, USA) as per
the manufacturer’s protocol. Then 1 × 105 transfected
cells were harvested and seeded in 0.1 % FBS medium
into the upper chamber, whereas medium supplemented
with 20 % FBS was applied to the lower chamber as a
chemo attractant for inducing invasion. After 48 h of in-
cubation, the migrant cells which were attached to the
lower surface were fixed in 4 % paraformaldehyde and
stained with crystal violet. The number of migrated cells
on the lower surface of the membrane was counted
under an invert microscope by examining 10 fields.
MTT assay and flow cytometry
Cell viability was measured using MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2-5 diphenyl tetrazolium bromide) assay.
5 × 103 cells were incubated in a 96-well culture plate for
24 h followed by their treatment with different concen-
trations of HCPT for 48 h. The supernatant was re-
moved and 180 μL cell culture fluid was added. 10 μL of
MTT (Sigma, M5665) dissolved in 100 μL of phosphate-
buffered saline (Sigma P4417) was added followed by in-
cubation for 4 h at 37 °C in a humid, 5 % CO2 atmos-
phere. After this, the supernatant was removed, and the
insoluble formazan crystals were dissolved in 150 μL of
dimethyl sulfoxide. The absorbance was read in a micro-
plate reader model 550 ELISA plate reader (BioRAD,
Hercules, USA) at 570 nm.
Statistical analysis
All statistical analyses were performed with SPSS version
13.0 software (SPSS, Chicago, IL, USA). The results of
IHC were analyzed using Pearson’s chi-square-test and
descriptive statistics. In-vitro results were expressed as
mean ± standard deviation, and the data were analyzed
for significance by ANOVA. A value of P <0.05 was con-
sidered to be statistically significant.
Results
Detection of RKIP and P-ERK expression in CRCT, NCRCT
and MLNT by immunostaining
The expression of RKIP was found throughout in the
cytoplasm of NCRCT and CRCT, with no significant dif-
ference between the two. However, the expression negli-
gible in MLNT. The protein expression of P-ERK was
positive in CRCT and MLNT, while it was negative in
NCRCT. P-ERK staining was also mainly in the cyto-
plasm, with occasional nuclear staining (Fig. 1). The
staining for RKIP was strong in NCRCT with “3+” and
in CRCT with “2+”, while only very weak staining was
detected in MLNT. The staining for P-ERK was very
weak in NCRCT with no “3+”, while strong staining was
there in NCRCT and CRCT. To summarize, RKIP ex-
pression levels were higher in CRCT and NCRCT than
in MLNT (χ2 = 36.446, **P <0.001). P-ERK expression
levels were higher in MLNT and NCRCT than in CRCT
(χ2 = 11.675, *P <0.05) (Table 1 and Fig. 2).
Role of RKIP expression in colonic cancer differentiation
We selected colon cell lines ranging from low-to-high
grade of differentiation. RKIP was detected in some part
of cytoplasm in all cell lines. The results showed that the
expression of RKIP were higher in well differentiated cell
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lines (HT-29, SW1116) than in poorly differentiated cell
lines (LoVo) (Fig. 3a). At the same time, RKIP mRNA
expressions in these colon cancer cell lines were also
illustrated by real-time PCR. RKIP expression was high-
est in SW1116 cell line and the lowest in LoVo cell line
(Fig. 3b: *P <0.05; **P <0.01). These results show the
consistency in the results attained by two different
approaches. The expression of RKIP was correlated to
the degree of tumor cell differentiation. The staining in-
tensity of RKIP protein decreased with the reducing
differentiation.
The sub clone cells stably expressing RKIP antisense RNA
were selected by G418 and named as SW1116/RKIP—.
The eukaryotic expression vector PIRES2-EGFP/PEBP-1
can up-regulate RKIP expression in LoVo cells
SW1116 with the highest RKIP protein in several cell
lines were transfected with RKIP shRNA by lipofecta-
mine and observed by fluorescence microscopy. The re-
sults showed a high transfection efficiency, while the
plasmid shRNA271 had an obvious interfering effect
(Fig. 4c). Positive clones were screened by G418 (Fig. 4a)
and identified by the green fluorescent protein (GFP) ex-
pression (Fig. 4b), and named SW1116/RKIP— cells. The
best screening concentration of G418 for SW1116 cells
was 800ug/mL. The results showed the single cell clone
all expression GFP (Fig. 4b). The RKIP protein expres-
sion was lower in SW1116/RKIP— than in SW1116 cells
(Fig. 4d). In the poorly differentiated LoVo cells, that
were transfected with the eukaryotic expression vector
pIRES2-EGFP/PEBP-1 plasmid, an up-regulation of
RKIP expression was observed (Fig. 4e).
Down-regulation of RKIP promotes invasion in SW1116
cells while its up-regulation inhibits invasion and migration
in LoVo cells
To investigate the role of RKIP in human colorectal can-
cer invasion and metastasis, matrigel invasion assay was
used to detect the difference of invasion and metastatic
ability in SW1116 cells, SW1116/ RKIP— cells, LoVo cells
and LoVo cells transfected with pIRES2-EGFP/PEBP-1.
Under the same culture conditions and inoculation
density, the down-regulation of RKIP in SW1116/RKIP—
increased the number of migrated cells on the lower sur-
face of the matrigel-coated transwell membrane (90.67 ±
4.04 vs. 37.33 ± 2.51, P <0.01) at 72 h. The up-regulation of
RKIP in LoVo cells transfected with pIRES2-EGFP/PEBP-1
reduced the number of migrated cells (79.24 ± 5.18 vs.
154.33 ± 7.25, P <0.05) at 72 h (Fig. 5). There were no cell
across the membrane at 24 h, and only few cells were
found across it in both the groups at 48 h.
Fig. 1 Immunohistochemical staining of NCRCT, CRCT and MLNT with anti-RKIP and anti-P-ERK antibody. Strong RKIP expression was stained
in NCRCT, CRCT; and weak in MLNT In contrast, P-ERK was weak to moderate in CRCT, MLNT, and no staining was observed in NCRCT. Mag-
nification x100; Red arrows indicate the enlarged areas in red frames. Abbreviations: RKIP, Raf kinase inhibitor protein; NCRCT, non neoplastic colo-
rectal tissue; CRCT, colorectal cancer tissue; MLNT, metastatic lymph node tissue




+ ++ +++ + ++ +++
NCRCT(30) 8 10 12 27 3 0
CRCT(30) 8 17 5 17 10 3
MLNT(30) 26 4 0 16 10 4
NCRCT, non neoplastic colorectal tissue; CRCT, colorectal cancer tissue; MLNT,
metastatic lymph node tissue; Statistical analysis: One-way analysis of variance
was followed by the student-newman-keuls post-hoc test. (**P <0.001,
*P <0.05)
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Fig. 2 The variable expression of RKIP protein and P-ERK protein in different tissues by clustered charts. X-axis represented a different tissue.
NCRCT: (N = 30); CRCT: (N = 30); MLNT: (N = 30); The positive staining of RKIP and P-ERK in different tissues are shown in Table 1. For RKIP: CRCT,
NCRCT vs. MLNT (x2 = 36.446 > × 20.05(4), **P <0.001). For P-ERK: MLNT, NCRCT vs. CRCT (x2 = 11.675 > x2 = 20.05(4), *P <0.05); Abbreviations: RKIP,
Raf kinase inhibitor protein; NCRCT, non neoplastic colorectal tissue; CRCT, colorectal cancer tissue; MLNT, metastatic lymph node tissue
Fig. 3 RKIP expression in colorectal cancer cell lines; a Immunohistochemical staining of colorectal cancer cell lines (LoVo, CaCO2, HT-29, SW1116)
with an RKIP antibody. RKIP expression was present in an area of the cytoplasm. RKIP was strongly stained in SW1116 cells. Hematoxylin was
used for nuclear staining (Magnification ×400); b mRNA expression of RKIP in cultured colorectal cancer cell lines. RKIP mRNA was detected
by RT-PCR analysis, in 4 colorectal cancer cell lines (LoVo, CaCO2, HT-29, SW1116). Abbreviations: RKIP, Raf kinase inhibitor protein; RT-PCR, reverse
transcriptase- polymerase chain reaction
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Fig. 4 Establishment of the single clone SW1116/RKIP— cells and effect of shRNA vector (PGPU6/GFP/Neo-PEBP1-501/271/376 targeted RKIP),
over-expression vector (pIRES2-EGFP/PEBP-1). a SW1116 cells stably transfected with shRNA 271 were screened with G418 in 800ug/mL to obtain
single colony selection in 24 well culture plates under optical microscope; b A under fluorescence microscope; c SW1116 cells were stably transfected
with either empty shRNA vector PGPU6/ GFP/Neo (SW1116 con) or shRNA vector PGPU6/GFP/Neo-PEBP1 -501/271/376 target RKIP (shRNA 501, 271,376)
respectively. RKIP expression was analyzed by Western Blot. shRNA 271 caused significant down-regulation of RKIP expression. d In SW1116/RKIP— cells,
Western Blot verified the decrease in RKIP expression. e LoVo control: LoVo cells transfected with empty pIRES2-EGFP; PEBP-1-a: LoVo cells transfected
with over-expression vector pIRES2-EGFP/PEBP-1, PEBP-1-b is repeated sample to PEBP-1-a. a, b, Magnification ×400). Abbreviations: RKIP, Raf
kinase inhibitor protein; NCRCT, non neoplastic colorectal tissue; CRCT, colorectal cancer tissue; MLNT, metastatic lymph node tissue; PEBP,
Phosphatidylethanolamine-binding proteins
Fig. 5 The effect of RKIP gene on invasiveness of cells: Significantly higher number of invasive cells in SW1116 /RKIP− cells with RKIP
down-regulation, as compared to SW1116 control cells (P <0.05); Decreased number of invasive cells in LoVo PEBP-1 compared to LoVo
con (P <0.05). Abbreviations: RKIP, Raf kinase inhibitor protein; LoVo PEBP-1, LoVo cells transfected with over-expression vector pIRES2-EGFP/PEBP-1;
LoVo con, LoVo control cells
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RKIP regulates cell cycle and the down-regulation of RKIP
inhibits G1 cell cycle arrest and promotes cell proliferation:
role of RKIP in cell cycle regulation
To avoid the impact of transfection reagent on cell cycle,
we selected SW1116/RKIP— cells with steady down-
regulation of RKIP expression, instead of SW1116 cells
transfected with RKIP shRNA. The percentage of cells at
S and G2/M phases by FCM was analysed by calculating
the PI. PI % = (S + G2/M)/(G0/G1 + S + G2/M)×100 was
calculated. Down-regulation of RKIP decreased the cells
in G0/G1 phase (48.6 ± 2.12 vs. 57.6 ± 3.35, P <0.05) and
increased the cells in G2/M phase (23.3 ± 4.31 vs. 14.9 ±
2.35, P <0.05), thereby increasing the PI (51.4 ± 2.12 vs.
42.4 ± 3.35, P <0.05) (Fig. 6). This suggests an important
effect of RKIP on the invasion and migration of SW1116
and LoVo cells, and that down-regulation of RKIP in-
hibits G1 cell cycle arrest and promotes cell prolifera-
tion. At the same time, LoVo cells transfected with
pIRES2-EGFP/PEBP-1 and LoVo cells transfected with
pIRES2-EGFP negative control plasmid were analyzed
through flow cytometry to observe the effect of over-
expression of RKIP gene on the ability of cell cycle.
There were no significant difference between the two
groups.
Down-regulation of RKIP inhibited chemosensitivity of
CRC cells to Hydroxycamptothecine
The effects of RKIP expression on the chemosensitiviy
of CRC to HCPT were observed by MTT (Fig. 7). The
results represent mean ± SD of three experiments.
Hydroxycamptothecin-resistant cell line (SW1116/HCPT),
derived from human colon cancer cell line SW1116 by
treatment with step-wise increasing concentrations of
HCPT has been described previously [22]. RKIP protein
expression levels were verified again (Fig. 7a). Down-
regulation of RKIP increased IC50 values of HCPT in
Fig. 6 The role of RKIP gene on cell cycle arrest and cell proliferation; cell cycle arrest and cell proliferation index as analyzed by flow cytometry:
Down-regulation of RKIP inhibited G1 cell cycle arrest and promoted cell proliferation. G0/G1 %, G2/M % and PI % are significantly higher in
SW1116/RKIP— cells with RKIP down-regulation, as compared to control SW1116 cells; Abbreviations: RKIP, Raf kinase inhibitor protein; PI %,
Proliferation index
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SW1116 cells: 1.176 mg/L (SW1116 con) vs. 0.410 mg/L
(SW1116 271) (Fig. 7b1); whereas up-regulation of RKIP
decreased the IC50 values of HCPT in SW1116/HCPT
cells: 1.891 mg/L (HCPT PEBP) vs. 6.374 mg/L (HCPT
CON) (Fig. 7b2). The results show that RKIP increases
chemosensitivity of CRC cells to HCPT.
Down-regulation of RKIP inhibits HCPT-induced apoptosis
After treatment with HCPT, SW1116 cells transfected
with shRNA 271 vector and control vector for 48 h were
analysed for evidence of apoptosis. As previously dem-
onstrated, shRNA 271 vector down-regulate the expres-
sion of RKIP. The apoptosis rate was lower in SW1116
cells transfected with shRNA 271 vector than that in
control cells (0.08 mg/mL: 6.91 % ± 1.03 % vs. 3.35 % ±
1.12 %; 0.16 mg/mL; 22.54 % ± 2.24 vs. 13.80 % ± 1.61,
P = 0.019 and P = 0.005, respectively; Fig. 8). It can be
inferred from these experiments that that the down-
regulation of RKIP inhibits the chemosensitivity of
CRC cells to HCPT by inhibiting apoptosis.
Discussion
Ras kinase inhibitor protein (RKIP) has been shown to be
associated with metastatic disease in an increasing number
of solid tumors. Dysregulation of RKIP expression can
potentially be associated with many malignancies. RKIP
Fig. 7 Effect of RKIP on sensitivity of CRC cells to hydroxycamptothecine (HCPT); a RKIP expression in each cell group. SW1116 con: SW1116 cells
transferred with empty pIRES2-EGFP vector; HCPT con: SW1116/HCPT cells transferred with empty pIRES2-EGFP vector; SW1116 271: SW1116 cells
transferred with shRNA vector targeted RKIP(PGPU6/GFP/Neo-PEBP1-271); HCPT PEBP-1: SW1116/HCPT cells transferred with over-expression
pIRES2-EGFP/PEBP-1 vector; b 5 × 103 cells incubated in 96-well culture plate for 24 h followed by treatment with different concentrations of HCPT
for 48 h. Cell survival rate determined by MTT assay. IC50 values of HCPT analyzed by SPSS software. Abbreviations: RKIP, Raf kinase inhibitor
protein, HCPT, hydroxycamptothecine; MTT: (3-(4,5-dimethylthiazol-2-yl)-2-5 diphenyl tetrazolium bromide) assay
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is initially expressed at a lower level in human metastatic
prostate cancer cells as compared to that in non-
metastatic cancer cells, and may have a role in preventing
vascular invasion of these cells [23]. RKIP expression is
significantly decreased in insulinomas [24], anaplastic
thyroid tumors [25], cutaneous squamous cell carcin-
oma [26], endometrial cancer [27], and hepatocellular
carcinoma [28]. Studies have also shown reduced RKIP
expression in lymph node metastases of breast and
melanoma cancer [29, 8].
Several studies have demonstrated an association of
RKIP with clinicopathological features in colorectal can-
cer. RKIP is depleted in distant metastases of both mis-
match repair proficient and deficient colorectal cancers
[18], and is a prognostic marker for disease-free survival
[20] and distant metastatic disease [30]. Loss of RKIP in
tumour buds has been frequently reported, with 60.8 %
of cases sustaining a complete loss in this area of CRC.
Moreover, the loss of RKIP can help predict the dynam-
ics of epithelial-mesenchymal transition (EMT) [31]. In
our study the RKIP expression was decreased in CRCT
when compared with NCRCT; but probably not to such
an extent.
To the best of our knowledge, no in vivo and in vitro
studies focusing on RKIP function in colorectal cancer
cells have been conducted. Immunostaining results ob-
tained in our study highlighted that RKIP is depleted in
lymph node metastases and the activation of ERK is
significant in CRC, both in-situ as well as in the CRC
cell lines and metastatic lymph node tissue. There was
a negative correlation between expression of RKIP and
P-ERK. Moreover, our study demonstrated that RKIP
expression was associated with the degree of differenti-
ation of colorectal cancer cells, with higher expression
occurring in well-differentiated cell lines (HT-29,
SW1116) than in poorly differentiated cell lines (LoVo).
Similarly, other studies have also demonstrated that
Raf/MEK/ERK signaling pathway is associated with not
only metastatic disease, but also differentiation in certain
cell lines [32]. RKIP can induce differentiation and re-
pression of cell proliferation in keratinocytes [33]. RKIP
contributes to the monocytic differentiation process via
inhibition of the NFkB signaling cascade, which is inde-
pendent from the canonical Ras/Raf/MEK/ERK pathway
[34]. Furthermore, RKIP has been shown to enhance neur-
onal differentiation via enhanced crosstalk from PKC to
ERK-1/2, and enhancement of G-protein-coupled receptor
signaling [35]. Some studies have suggested that RKIP
may be dissociated from Raf-1 after phosphorylation at
serine 153 by PKC. In effect, PKC appears to relieve a key
Fig. 8 Apoptosis induction by hydroxycamptothecine (HCPT) in two group cells. Each group was treated with HCPT for 48 h at 0.08 mg/L,
0.16 mg/L concentrations. 1 × 106 cells were collected and analyzed by flow cytometry after staining with Annexin V/PI
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inhibitor of the Raf/MAP kinase signaling cascade [36].
As time constraints did not allow for a differential gene
expression analysis, the details of underlying signaling
pathway could not be determined.
Poorly differentiated LoVo cells transiently transfected
with pIRES2-EGFP/PEBP-1 plasmid to cause over-
expression of RKIP, were tested in matrixgel invasion
and cell cycle assay. Over-expression of RKIP was found
to inhibit invasion, but did not affect cell cycle and PI of
LoVo cells. However, loss of RKIP function was found to
inhibit G1 cell cycle arrest and increase cell PI (PI %) in
SW1116 cells (Fig. 6, PI: 51.4 ± 2.12 vs. 42.4 ± 3.35) in
our study, the difference of PI is less than one fold;
While the down-regulation of RKIP in SW1116/RKIP—
increased the number of migrated cells on the lower sur-
face of the matrigel-coated transwell membrane (Fig. 5,
90.67 ± 4.04 vs. 37.33 ± 2.51, P <0.01), the difference is
two to three folds. The cell proliferation could compli-
cate the interpretation of the results probably, but we
thought that the role of cell invasion was more signifi-
cant than the cell proliferation in results concluded from
Fig. 5 in our study.
SW1116/RKIP— cells with stable down-regulation of
RKIP expression were developed in our study, which
perhaps minimized experimental error and cytotoxicity,
as seen with the use of commercial liposome-based
agents. Lipofectamine 2000, a cationic liposome based
reagent, can change expression of marker genes for cell
cycle inhibition or progression, such as p21 and PCNA,
and also shows decrease in viability and DNA content
[37]. We found that stable transfection as compared to
transient transfection was more advantageous in terms
of cell cycle assay.
A natural indole alkaloid extracted from a Chinese tree
Camptotheca cuminata, HCPT is a topoisomerase I-
specific inhibitor [38]. Available evidence shows that
HCPT can induce apoptosis in multiple cancers [39],
and can also inhibit metastatic colorectal cancer [40].
HCPT treatment activates caspase 3, and down regulates
the expression of surviving [41]. Multidrug resistance
gene ABCG2 and cell cycle related gene p21 had high
expression in SW1116/HCPT cells [42, 22]. In our study,
RKIP promoted cell apoptosis induced by HCPT, while
the down-regulation of RKIP expression inhibited cell
cycle arrest. Cell cycle capture allows cells to stop prolifer-
ating and repair the damage in order to continue cell div-
ision. Expression of p21 can protect cells from apoptosis
induced by anticancer drugs. P21 is probably involved
in RKIP regulated apoptosis induced by HCPT. RKIP
overexpression appears to regulate tumor cell sensitivity
to TRAIL by inhibiting YY1 and up-regulating DR5. RKIP
overexpression in combination with TRAIL has been
shown to potentiate the above effects and activate cas-
pases 8, 9, and 3, resulting in apoptosis [43].
Conclusions
In summary, RKIP is not only a metastasis inhibitor factor,
but also related with colorectal cancer cell differentiation.
Loss of RKIP inhibits cell cycle arrest and promotes cell
proliferation. Furthermore, down-regulation of RKIP re-
duced chemosensitivity by inhibiting apoptosis induced by
HCPT. Our findings suggest that further investigation into
the pathophysiological mechanisms of RKIP may help
develop new therapeutic strategies for the treatment of
colorectal cancer. Moreover, RKIP may serve as an im-
mune surveillance cancer gene since its low expression
(or absence) may serve as a marker for a likely poor im-
mune response, that could serve to shield the tumor
cells against the host cytotoxic effector cells.
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